Trial Profile
A Pilot Study on the Effect of Privigen Against Graft Loss: Interventional Study of Kidney Transplant Recipients at Risk for Graft Loss Through Antibody-mediated Rejection
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Immune globulin (Primary)
- Indications Renal transplant rejection
- Focus Therapeutic Use
- Acronyms InAuGuRAL
- 08 Mar 2021 Status changed from active, no longer recruiting to completed.
- 10 Feb 2021 Planned End Date changed from 31 Dec 2020 to 31 Dec 2021.
- 07 Sep 2020 Planned End Date changed from 1 Feb 2019 to 31 Dec 2020.